These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24419118)

  • 1. Are dose-dense and triplet chemotherapy regimens optimal adjuvant therapy in the majority of women with node-positive early breast cancer?
    Moylan EJ; Connell LC; O'Reilly S
    J Clin Oncol; 2014 Feb; 32(6):605-6. PubMed ID: 24419118
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
    Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
    Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant docetaxel for node-positive breast cancer.
    Noronha V
    N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16136712
    [No Abstract]   [Full Text] [Related]  

  • 4. Dose-dense chemotherapy for breast cancer: what does the future hold?
    Morris PG; McArthur HL; Hudis C; Norton L
    Future Oncol; 2010 Jun; 6(6):951-65. PubMed ID: 20528233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    Wolowacz SE; Cameron DA; Tate HC; Bagust A
    J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.
    Barroso-Sousa R; Paes FR; Vaz-Luis I; Batista RB; Costa RB; Losk K; Camuso K; Metzger-Filho O; Hughes ME; Bunnell CA; Golshan M; Winer EP; Lin NU
    Breast; 2016 Dec; 30():136-140. PubMed ID: 27721193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer.
    de Graaf H; Willemse PH; Bong SB; Piersma H; Tjabbes T; van Veelen H; Coenen JL; de Vries EG
    Oncology; 1996; 53(4):289-94. PubMed ID: 8692532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cancer of the breast in young women: should chemotherapy be intensified?].
    Piccart MJ
    Pathol Biol (Paris); 1992 Nov; 39(9):843-4. PubMed ID: 1371604
    [No Abstract]   [Full Text] [Related]  

  • 9. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
    Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA; Bermejo B; Gallardo E; Vidal R; Vera R; Eres N; Carulla J; Baselga J
    J Clin Oncol; 1996 May; 14(5):1573-80. PubMed ID: 8622074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer.
    Burstein HJ
    Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):13-5. PubMed ID: 17370924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant docetaxel for node-negative breast cancer.
    Venniyoor A
    N Engl J Med; 2011 Mar; 364(10):976-7; author reply 977-8. PubMed ID: 21388324
    [No Abstract]   [Full Text] [Related]  

  • 12. Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.
    Martin M; Vogel C; Crown J; Mackey J
    JAMA; 2005 Nov; 294(17):2166; author reply 2166-7. PubMed ID: 16264153
    [No Abstract]   [Full Text] [Related]  

  • 13. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
    Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
    Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
    Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
    J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Sweet syndrome during therapy with granulocyte colony-stimulating factor.
    Park JW; Mehrotra B; Barnett BO; Baron AD; Venook AP
    Ann Intern Med; 1992 Jun; 116(12 Pt 1):996-8. PubMed ID: 1375012
    [No Abstract]   [Full Text] [Related]  

  • 18. Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: an analysis of 1655 patients.
    Chan A; McGregor S; Liang W
    Breast; 2014 Oct; 23(5):676-82. PubMed ID: 25108452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey.
    Falandry C; Krakowski I; Curé H; Carola E; Soubeyran P; Guérin O; Freyer G
    Anticancer Res; 2014 Sep; 34(9):5007-15. PubMed ID: 25202084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.